Round Up

Five things for pharma marketers to know: Monday, October 16, 2017

Five things for pharma marketers to know: Monday, October 16, 2017

By

FDA briefing document affirms diabetes drug's efficacy; J&J debuts new tools to improve adherence; AZ says cancer drug data was falsified

Five things for pharma marketers to know: Friday, October 13, 2017

Five things for pharma marketers to know: Friday, October 13, 2017

By

Outcome Health reportedly misled advertisers; FDA committee recommends gene therapy; Avanir drug is highly prescribed by docs paid by company

Five things for pharma marketers to know: Wednesday, October 4, 2017

Five things for pharma marketers to know: Wednesday, October 4, 2017

By

The FDA approves Mylan's Copaxone generic; 3 out of every 1,000 Americans face $50,000 in drug costs; some ACA premiums may rise by 50%

Five things for pharma marketers to know: Tuesday, October 3, 2017

Five things for pharma marketers to know: Tuesday, October 3, 2017

By

The FDA wants to improve the generic drug approval process; Allergan CEO responds to criticism of patent deal; breast cancer death rate dropped 40%

Five things for pharma marketers to know: Friday, September 22, 2017

Five things for pharma marketers to know: Friday, September 22, 2017

By

Express Scripts' Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts

Five things for pharma marketers to know: Wednesday, September 20, 2017

Five things for pharma marketers to know: Wednesday, September 20, 2017

By

Pfizer sues J&J over Remicade contracts; drugmakers trim sales forces for rare-disease drugs; Roche's oncology business under siege from biosimilars

Five things for pharma marketers to know: Thursday, September 14, 2017

Five things for pharma marketers to know: Thursday, September 14, 2017

By

One-third of clinical trials are never publicly registered; ICER revises PCSK9 cost-effectiveness analysis; flu shot linked to miscarriages

Five things for pharma marketers to know: Wednesday, September 13, 2017

Five things for pharma marketers to know: Wednesday, September 13, 2017

By

FDA closes pediatric study loophole; little evidence outcomes-based contracts are working; PBMs lobby against transparency efforts

Five things for pharma marketers to know: Tuesday, September 12, 2017

Five things for pharma marketers to know: Tuesday, September 12, 2017

By

Alexion to cut 600 jobs; Sage Therapeutics' experimental seizure drug fails to meet expectations; Apple is interested in medical and health activity

Five things for pharma marketers to know: Monday, September 11, 2017

Five things for pharma marketers to know: Monday, September 11, 2017

By

Teva names new CEO; Allergan transfers Restasis patent to skirt competition; Google invests in oncology

Five things for pharma marketers to know: Friday, September 8, 2017

Five things for pharma marketers to know: Friday, September 8, 2017

By

Pfizer receives warning letter over EpiPen manufacturing; Opdivo kidney-cancer trial shows improved survival rates; cancer patients who discuss costs with physicians pay less

Five things for pharma marketers to know: Thursday, September 7, 2017

Five things for pharma marketers to know: Thursday, September 7, 2017

By

The FDA halts IO-combo trial for Opdivo; Lilly slashes 3,500 jobs; new asthma drug could treat wide range of patients

Five things for pharma marketers to know: Wednesday, September 6, 2017

Five things for pharma marketers to know: Wednesday, September 6, 2017

By

The FDA warns drugmaker over opioid promotion; Watson may not be living up to the hype; Merck acquires immuno-oncology biotech

Five things for pharma marketers to know: Monday, August 28, 2017

Five things for pharma marketers to know: Monday, August 28, 2017

By

Gilead to acquire Kite; the FDA issues fewest number of warning letters since 2008; the regulator approves BI's Humira biosimilar

Five things for pharma marketers to know: Tuesday, August 22, 2017

Five things for pharma marketers to know: Tuesday, August 22, 2017

By

Novartis launches MS study with Apple's ResearchKit; the FDA considering limiting risk info in drug ads; J&J loses baby powder lawsuit

Five things for pharma marketers to know: Friday, August 11, 2017

Five things for pharma marketers to know: Friday, August 11, 2017

By

Egalet slashes workforce in favor of opioid education; Novo's experimental obesity drug reports positive results; Trump declares opioid crisis a national emergency

Five things for pharma marketers to know: Thursday, August 3, 2017

Five things for pharma marketers to know: Thursday, August 3, 2017

By

FDA committee votes against J&J arthritis drug; scientists successfully edit genes; Shire mulls ADHD spin off

Five things for pharma marketers to know: Friday, July 14, 2017

Five things for pharma marketers to know: Friday, July 14, 2017

By

The FDA approves J&J psoriasis drug; PARP inhibitors are not cost-effective, ICER says; Verily releases mosquitoes to combat Zika

Five things for pharma marketers to know: Wednesday, July 5, 2017

Five things for pharma marketers to know: Wednesday, July 5, 2017

By

Amgen and Teva raise prices of leukemia drugs twice this year; Roche acquires diabetes app; docs use Snapchat to share patient scans

Five things for pharma marketers to know: Friday, June 30, 2017

Five things for pharma marketers to know: Friday, June 30, 2017

By

The FDA plans to review orphan drug backlog; drugmaker supported charity helped patients pay for donor's drugs; low dose Xarelto gets Priority Review

Five things for pharma marketers to know: Wednesday, June 28, 2017

Five things for pharma marketers to know: Wednesday, June 28, 2017

By

Lawmakers delay healthcare bill vote; Merck affected by cyberattack; more young people are having strokes

Five things for pharma marketers to know: Monday, June 26, 2017

Five things for pharma marketers to know: Monday, June 26, 2017

By

The performance of generic drugs is not always guaranteed; the FDA approves a new blood thinner; Gottlieb wants rejection letters public

Five things for pharma marketers to know: Friday, June 23, 2017

Five things for pharma marketers to know: Friday, June 23, 2017

By

Novartis drug prevents heart attacks and strokes, per trial; Senate lawmakers unveil healthcare bill; Pfizer receives CRL for Epogen biosimilar

Five things for pharma marketers to know: Tuesday, June 20, 2017

Five things for pharma marketers to know: Tuesday, June 20, 2017

By

Novartis reports positive Phase-III results for Eylea competitor; AZ faces "critical transition point" in MYSTIC trial; physician shortage expected to rise

Five things for pharma marketers to know: Tuesday, June 13, 2017

Five things for pharma marketers to know: Tuesday, June 13, 2017

By

Alkermes lobbies lawmakers on its opioid addiction drug; rep salaries rise; SCOTUS rules in favor of Sandoz in biosimilar suit

Five things for pharma marketers to know: Thursday, June 8, 2017

Five things for pharma marketers to know: Thursday, June 8, 2017

By

Novartis CAR-T drug boasts competitive response rates; WPP reports slowing sales for healthcare business; AZ sells migraine drug

Five things for pharma marketers to know: Wednesday, May 31, 2017

Five things for pharma marketers to know: Wednesday, May 31, 2017

By

BMS partners on Opdivo combo; one-quarter of insurers have signed an outcomes-based contract with a drugmaker; rebates do not lead to savings for Medicare beneficiaries

Five things for pharma marketers to know: Wednesday, May 24, 2017

Five things for pharma marketers to know: Wednesday, May 24, 2017

By

Keytruda receives first approval based on a genetic feature and not tumor's location; Alexion reps reportedly crossed ethical lines; profits up at insurers

Five things for pharma marketers to know: Monday, May 22, 2017

Five things for pharma marketers to know: Monday, May 22, 2017

By

Amgen's osteoporosis drug set back by safety issue; new FDA digital biz to hire 13 engineers; Celgene's MS drug bests Avonex in trial

Five things for pharma marketers to know: Friday, May 19, 2017

Five things for pharma marketers to know: Friday, May 19, 2017

By

Keytruda gets two new FDA approvals; lawmakers aim to speed up approval of generics; Incyte uses soap opera to spread rare-disease awareness